Business ❯ Pharmaceutical Industry ❯ Regulatory Affairs

FDA

Drug Approval Process Biologics License Application Drug Review Process Therapeutics Orphan Drug Designation Corporate Governance Sarepta Therapeutics

FDA Rejects Regenxbio’s Hunter Syndrome Gene Therapy Application

Regenxbio plans a Type A meeting to present longer-term data with expert analyses for a swift resubmission.

Former FDA Biologics Chief Peter Marks Joins Eli Lilly to Lead Infectious Disease and Molecule Discovery

Moderna Withdraws Flu-COVID Vaccine Application After FDA Requests More Data